Bifunctional role of pro-inflammatory cytokines after traumatic brain injury

Brain Injury

Volumn 30, Issue 9, 2016, Pages 1043-1053

  Sordillo, Peter P ^a   Sordillo, Laura A ^a   Helson, Lawrence ^a  

^a SignPath Pharma Inc   (United States)

Author keywords

brain rehabilitation; Inflammation; interleukin 1; interleukin 6; neurologic damage; progestins; statins; tetracyclines; tumour necrosis factor

Indexed keywords

ANTIINFLAMMATORY AGENT; CYTOKINE; GESTAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; TETRACYCLINE DERIVATIVE; TUMOR NECROSIS FACTOR;

BRAIN DAMAGE; BRAIN LEVEL; CEREBROSPINAL FLUID LEVEL; CYTOKINE RELEASE; DRUG TARGETING; HUMAN; INFLAMMATION; NONHUMAN; REVIEW; TRAUMATIC BRAIN INJURY; ANIMAL; BRAIN; BRAIN INJURY; DISEASE MODEL; METABOLISM; PATHOLOGY;

ANIMALS; BRAIN; BRAIN INJURIES; CYTOKINES; DISEASE MODELS, ANIMAL; INFLAMMATION;

EID: 84983650217     PISSN: 02699052     EISSN: 1362301X     Source Type: Journal    
DOI: 10.3109/02699052.2016.1163618     Document Type: Review

References (193)

1. I.A.Clark, L.M.Alleva, A.C.Budd, W.B.Cowden Understanding the role of inflammatory cytokines in malaria and related diseases. Travel Medicine & Infectious Disease 2008;6:67–81.
2. K.J.Huang, I.J.Siu, M.Theron, Y.C.Wu, C.C.Liu, H.Y.Lei An interferon-gamma related cytokine storm in SARS patients. Journal of Medical Virology 2005;75:185–194.
3. L.A.Espada-Murao, K.Morita Dengue and soluble mediators of the innate immune system. Tropical Medicine & Health 2011;39:53–62.
4. E.A.G.Reis, J.E.Hagan, G.S.Ribeiro, A.Teixeira-Carvalho, O.A.Martins-Filho, R.R.Montgomery, A.C.Shaw, A.I.Ko, M.G.Reis Cytokine response signatures in disease progression and development of severe clinical outcomes for leptospirosis. PLoS Neglected Tropical Diseases 2013;7:e2457.
5. L.M.Branco, J.N.Grove, M.L.Boisen, J.G.Shaffer, A.Goba, M.Fullah, M.Momob, D.S.Grant, R.F.Garry Emerging trends in Lassa fever. Redefining the role of immunoglobulin M and inflammation in diagnosing acute infection. Virology Journal 2011;8:478.
6. H.C.Sepsis:Harrison C. calming the cytokine storm. Nature Reviews Drug Discovery 2010;9:360–361.
7. I.A.Clark The advent of the cytokine storm. Immunology & Cell Biology 2007;85:271–273.
8. R.V.D’Elia, K.Harrison, P.C.Oyston, R.A.Lukaszewski, G.C.Clark Targeting the ‘cytokine storm ‘ for therapeutic benefit. Clinical & Vaccine Immunology 2013;20:319–327.
9. Y.Sun, C.Jin, F.Zhan, X.Wang, M.Liang, Q.Zhang, S.Ding, X.Guan, X.Huo, C.Li, et al. Host cytokine storm is associated with disease severity of severe fever with thrombocytopenia syndrome. Journal of Infectious Disease 2012;206:1085–1094.
10. S.C.Johnston, J.C.Johnson, S.W.Stonier, K.L.Lin, N.K.Kisalu, L.E.Hensley, A.W.Rimoin Cytokine modulation correlates with severity of monkeypox disease in humans. Journal of Clinical Virology 2015;63:42–45.
11. N.Wauquier, P.Becquart, C.Padilla, S.Baize, E.M.Leroy Human fatal Zaire Ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Neglected Tropical Diseases 2010;4:e837.
12. P.P.Sordillo, L.Helson Curcumin suppression of cytokine release and cytokine storm. A potential therapy for patients with Ebola and other severe viral infections. In Vivo. 2015;29:1–4.
13. M.Mohamadzadeh, L.Chen, A.L.Schmaljohn H.EbolaHow and Marburg viruses battle the immune system. Nature Reviews Immunology 2007;7:556–567.
14. J.R.Tisonick, M.J.Korth, C.P.Simmons, J.Farrar, T.R.Martin, M.G.Katze Into the eye of the cytokine storm. Microbiology & Molecular Biology Reviews 2012;76:16–32.
15. J.R.Teijaro, K.B.Walsh, S.Rice, H.Rosen, M.B.A.Oldstone Mapping the innate signaling cascade essential for cytokine storm during influenza virus infection. Proceedings of the National Academy of Sciences 2014;111:3799–3804.
16. R.Goa, J.Bhatnagar, D.M.Blau, P.Greer, D.C.Rollin, A.M.Denison, M.Deleon-Carnes, W.J.Shieh, S.Sambhara, T.M.Tumpey, et al. Cytokine and chemokine profiles in lung tissue from fatal cases of 2009 pandemic influenza A (H1N1):Role of the host immune response in pathogenesis. American Journal of Pathology 2013;183:1258–1268.
17. N.Aikawa Cytokine storm in the pathogenesis of multiple organ dysfunction syndrome associated with surgical insults. Nihon Geka Gakkei Zasshi 1996;97:771–777.
18. R.Makhija, A.N.Kingsnorth Cytokine storm in acute pancreatitis. Journal of Hepatobiliary Pancreatic Surgery 2002;9:401–410.
19. W.Y.Park, R.B.Goodman, K.P.Steinberg, J.T.Ruzinsky, F.Rudella, D.R.Park, J.Pugin, S.J.Skeritt, L.D.Hudson, T.R.Martin Cytokine balance in the lungs of patients with acute respiratory distress syndrome. American Journal of Respiratory & Critical Care Medicine 2001;164:1896–1903.
20. J.L.Ferrara, S.Abhyankar, D.G.Gilliland Cytokine storm of graft-versus-host disease:a critical effector role for interleukin-1. Transplant Proceedings 1993;25:1216–1217.
21. M.Mohty, D.Blaise, C.Faucher, N.Vey, R.Bouabdallah, A.M.Stoppa, F.Viret, G.Gravis, D.Olive, B.Gaugler Inflammatory cytokines and acute graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2005;106:4407–4411.
22. C.Kanaris, R.F.Wynn, A.Konstantinidis G408(P) cytokine storm associated multi-organ failure with poor neurological outcome during rituximab administration in a child with relapsed acute lymphoblastic leukaemia and ebv related lymphoproliferative disease. Archives of Disease in Childhood 2015;100:A168.
23. P.J.Bugelski, R.Achuthanandam, R.J.Capocasale, G.Treacy, E.Bournan-Thio Monoclonal antibody-induced cytokine-release syndrome. Expert Review of Clinical Immunology 2009;5:499–521.
24. W.Swardfager, K.Lanctot, L.Rothenburg, A.Wong, J.Cappell, N.Hermann A meta-analysis of cytokines in Alzheimer’s disease. Biological Psychiatry 2010;68:930–941.
25. T.Nagatsu, M.Mogi, H.Ichinose, A.Togari Cytokines in Parkinson’s disease. Journal of Neural Transmission Supplement 2000;58:143–151.
26. N.Xu, X.Li, Y.Zhong Inflammatory cytokines:potential biomarkers of immunologic dysfunction in autism spectrum disorders. Mediators of Inflammation 2015;531518.
27. V.Navikas, L.H.Review:Link H. cytokines and the pathogenesis of multiple sclerosis. Journal of Neuroscience Research 1996;45:322–333.
28. K.K.Nyati, K.N.Prasad Role of cytokines and toll-like receptors in the immunopathogenesis of Guillain-Barre syndrome. Mediators of Inflammation 2014:758639.
29. M.O.Lu, J.Zhu The role of cytokines in Guillain-Barre syndrome. Journal of Neurology 2011;258:533–548.
30. S.Najjar, D.M.Pearlman, K.Alper, A.Najjar, O.Devinsky Neuroinflammation and psychiatric illness. Journal of Neuroinflammation 2013;10:43–66.
31. R.R.Girgis, S.S.Kumar, A.S.Brown The cytokine model of schizophrenia:emerging therapeutic strategies. Biological Psychiatry 2014;75:292–299.
32. E.Trysberg, H.Carlsten, A.Tarkowski Intrathecal cytokines in systemic lupus erythematosus with central nervous system involvement. Lupus 2000;9:498–503.
33. H.Okamoto, A.Kobayashi, H.Yamanaka Cytokines and chemokines in neuropsychiatric syndromes of systemic lupus erythematosus. Journal of Biomedicine & Biotechnology 2010;268436:1–8.
34. B.Roozenbeck, A.I.R.Maas, D.K.Menon Changing patterns in the epidemiology of traumatic brain injury. Nature Reviews Neurology 2013;9:231–236.
35. M.Fork, C.Bartels, A.D.Ebert, C.Grubich, H.Synowitz, C.W.Wallesch Neuropsychological sequelae of diffuse traumatic brain injury. Brain Injury 2005;19:101–108.
36. E.Dardiotis, V.Karanikas, K.Paterakis, K.Fountas, G.M.Hadjigeorgiou Traumatic brain injury and inflammation:emerging role of innate and adaptive immunity. In:A.Agrawal, editor. Brain injury- pathogenesis, monitoring, recovery and management. Croatia:In Tech; 2012.
37. B.Maier, H.L.Laurer, S.Rose, W.A.Buurman, I.Marzi Physiological levels of pro- and anti-inflammatory mediators in cerebrospinal fluid and plasma:a normative study. Journal of Neurotrauma 2005;22:822–835.
38. T.Woodcock, M.C.Morganti-Kossmann The role of markers of inflammation in traumatic brain injury. Frontier in Neurology 2013;4:1–18.
39. T.Kossmann, V.Hans, H.G.Imhof, O.Trentz, M.C.Morganti-Kossman Interleukin-6 released in human cerebrospinal fluid following traumatic brain injury may trigger nerve growth factor production in astrocytes. Brain Research 1996;713:143–152.
40. T.Kossmann, V.H.Hans, H.G.Imhof, R.Stocker, P.Grob, O.Trentz, C.Morganti-Kossman Intrathecal and serum interleukin-6 and the acute-phase response in patients with severe traumatic brain injuries. Shock 1995;4:311–317.
41. H.Kushi, T.Saito, K.Makino, N.Hayashi IL-8 is a key mediator of inflammation in severe traumatic brain injuries. Acta Neurochirurgica Supplement 2003;86:347–350.
42. A.Helmy, K.L.H.Carpenter, D.K.Menon, J.D.Pickard, P.J.A.Hutchinson The cytokine response to human traumatic brain injury:temporal profiles and evidence for cerebral parenchymal production. Journal of Cerebral Blood Flow & Metabolism 2011;31:658–670.
43. M.Arand, H.Melzner, L.Kinzl, U.B.Bruckner, F.Gebhard Early inflammatory mediator response following isolated traumatic brain injury and other major trauma in humans. Langenbecks Archives of Surgery 2001;386:241–248.
44. C.Woiciechowsky, B.Schoning, J.Cobanov, W.R.Lanksch, H.D.Volk, W.D.Docke Early IL-6 plasma concentrations correlate with severity of brain injury and pneumonia in brain-injured patients. Journal of Trauma 2002;52:339–345.
45. P.M.Lenzlinger, M.C.Morganti-Kossmann, H.L.Laurer, T.K.McIntosh The duality of the inflammatory response to traumatic brain injury. Molecular Neurobiology 2001;24:169–181.
46. I.Figiel Pro-inflammatory cytokine TNF-α as a neuroprotective agent in the brain. Acta Neurobiologiae Experimentalis (Wars) 2008;68:526–534.
47. M.C.Morganti-Kossmann, P.M.Lenzlinger, V.Hans, P.Stahel, E.Csuka, E.Ammann, R.Stocker, O.Trentz, T.Kossmann Production of cytokines following brain injury:beneficial and deleterious for the damaged tissue. Molecular Psychiatry 1997;2:133–136.
48. K.Baruch, N.Rosenzweig, A.Kertser, A.Deczkowska, A.M.Sharif, S.A.Tsitsou-Kampeli, A.Sarel, L.Cahalon, M.Schwartz Breaking immune tolerance by targeting Foxp3(+) regulatory T cells mitigates Alzheimer’s disease pathology. Nature Communications 2015;6:7967.
49. G.Martino, S.Pluchino, L.Bonfanti, M.Schwartz Brain regeneration in physiology and pathology:the immune signature driving therapeutic plasticity of neural stem cells. Physiological Reviews 2011;91:1281–304.
50. M.Schwartz, K.Baruch The resolution of neuroinflammation in neurodegeneration:leukocyte recruitment via the choroid plexus. EMBO Journal 2014;33:7–22.
51. M.Schwartz, K.Baruch Breaking peripheral immune tolerance to CNS antigens in neurodegenerative diseases:boosting autoimmunity to fight-off chronic neuroinflammation. Journal of Autoimmunity 2014;54:8–14.
52. G.Kunis, K.Baruch, N.Rosenzweig, A.Kertser, O.Miller, T.Berkutzki, M.Schwartz IFN-γ-dependent activation of the brain’s choroid plexus for CNS immune surveillance and repair. Brain 2013;136:3427–3440.
53. U.Scherbel, R.Raghupathi, M.Nakamura, K.E.Saatman, J.Q.Trojanowski, E.Neugebauer, M.W.Marino, T.K.McIntosh Differential acute and chronic responses of tumor necrosis factor-deficient mice to experimental brain injury. Proceedings of the National Academy of Science 1999;96:8721–8726.
54. I.L.Campbell, C.R.Abraham, E.Masliah, P.Kemper, J.D.Inglis, M.B.Oldstone, L.Mucke Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proceedings of the National Academy of Sciences USA 1993;90:10061–10065.
55. C.A.Dinarello Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011;117:3720–3732.
56. A.Weber, P.Wasiliew, M.Kracht Interleukin-1 (IL-1) pathway. Science Signaling 2010;3:cm1.
57. E.Voronov, D.S.Shouval, Y.Krelin, E.Cagnano, D.Benharroch, Y.Iwakura, C.A.Dinarello, R.N.Apte IL-1 is required for tumor invasiveness and angiogenesis. Proceedings of the National Academy of Sciences USA 2003;100:2645–2650.
58. P.P.Sordillo, L.Helson Curcumin and cancer stem cells:curcumin has asymmetrical effects on cancer and normal stem cells. Anticancer Research 2015;35:599–614.
59. R.Yirmiya, G.Winocur, I.Goshen Brain interleukin-1 is involved in spatial memory and passive avoidance conditioning. Neurobiology & Learning & Memory 2002;78:379–89.
60. D.Giulian, J.Woodward, D.G.Young, J.F.Krebs, L.B.Lachman Interleukin-1 injected into mammalian brain stimulates astrogliosis and neovascularization. Journal of Neuroscience 1988;8:2485–2490.
61. S.S.Shaftel, W.S.Griffin, M.K.O’Banion The role of interleukin-1 in neuroinflammation and Alzheimer disease:an evolving perspective. Journal of Neuroinflammation 2008;5:7.
62. A.Singhal, A.J.Baker, G.M.Hare, F.X.Reinders, L.C.Schlichter, R.J.Moulton Association between cerebrospinal fluid interleukin-6 concentrations and outcome after severe human traumatic brain injury. Journal of Neurotauma 2002;19:929–939.
63. T.Frugier, M.C.Morganti-Kossmann, D.O’Reilly, C.A.McLean In situ detection of inflammatory mediators in post mortem human brain tissue after traumatic injury. Journal of Neurotrauma 2010;27:497–507.
64. T.Shiozaki, T.Hayakata, O.Tasaki, H.Hosotubo, K.Fuijita, T.Mouri, G.Tajima, K.Kajino, H.Nakae, H.Tanaka, et al. Cerebrospinal fluid concentrations of anti-inflammatory mediators in early-phase severe traumatic brain injury. Shock 2005;23:406–410.
65. T.Hayakata, T.Shiozaki, O.Tasaki, H.Ikegawa, Y.Inoue, F.Toshiyuki, H.Hosotubo, F.Kieko, T.Yamashita, H.Tanaka, et al. Changes in CSF S-100B and cytokine concentrations in early-phase severe traumatic brain injury. Shock 2004;22:102–107.
66. K.Kamm, W.Vanderkolk, C.Lawrence, M.Jonker, A.T.Davis The effect of traumatic brain injury upon concentration and expression of interleukin-1beta and interleukin-10 in the rat. Journal of Trauma 2006;60:152–157.
67. H.Shojo, Y.Kaunko, T.Mabuchi, K.Kibayashi, N.Adachi, C.V.Borlongan Genetic and histologic evidence implicates role of inflammation in traumatic brain injury-induced apoptosis in the cerebral cortex following moderate fluid percussion injury. Neuroscience 2010;171:1273–1282.
68. M.Maegele, S.Saneriand, B.Bouillon, U.Schafer, H.Trubel, P.Riess, E.A.M.Neugebauer Differential immunoresponses following experimental traumatic brain injury, bone fracture and ‘two-hit’ -combined neurotrauma. Inflammation Research 2007;56:318–323.
69. B.D.Semple, N.Bye, M.Rancan, J.M.Ziebell, M.C.Morganti-Kossmann Role of CCL2 (MCP-1) in traumatic brain injury (TBI):evidence from severe TBI patients and CCL2-/- mice. Journal of Cerebral Blood Flow & Metabolism 2010;30:769–782.
70. K.Lu, Y.W.Wang, Y.Y.Wo, Y.L.Yang Extracellular signal-regulated kinase-mediated IL-1-induced cortical neuron damage during traumatic brain injury. Neuroscience Letters 2005;386:40–45.
71. H.C.Patel, H.Boutin, Allan SM:Interleukin-1 in the brain. Mechanisms of action in acute neurodegeneration. Annals of the New York Academy of Sciences 2003;992:39–47.
72. G.P.Schielke, G.Y.Yang, B.D.Shivers, A.L.Betz Reduced ischemic brain injury in interleukin-1 beta converting enzyme-deficient mice. Journal of Cerebral Blood Flow & Metabolism 1998;18:180–185.
73. G.Y.Yang, X.H.Liu, C.Kadoya, Y.J.Zhao, Y.Mao, B.L.Davidson, A.L.Betz Attenuation of ischemic inflammatory response in mouse brain using an adenoviral vector to induce overexpression of interleukin-1 receptor antagonist. Journal of Cerebral Blood Flow & Metabolism 1998;18:840–847.
74. N.C.Jones, M.J.Prior, E.Burden-Teh, C.A.Marsden, P.G.Morris, S.Murphy Antagonism of the interleukin-1 receptor following traumatic brain injury in the mouse reduces the number of nitric oxide synthase-2-positive cells and improves anatomical and functional outcomes. European Journal of Neuroscience 2005;22:72–78.
75. K.L.Sanderson, R.Raghupathi, K.E.Saatman, D.Martin, G.Miller, T.K.McIntosh Interleukin-1 receptor antagonist attenuates regional neuronal cell death and cognitive dysfunction after experimental brain injury. Journal of Cerebral Blood Flow & Metabolism 1999;19:1118–1125.
76. A.E.Hasturk, E.R.Yilmaz, E.Turkoglu, H.Kertmen, B.Horasanli, N.Hayirli, I.B.Erguder, O.Evirgen Therapeutic evaluation of interleukin 1-beta antagonist Anakinra against traumatic brain injury in rats. Ulus Travma Acil Cerrahi Derg 2015;21:1–8.
77. J.K.Relton, N.J.Rothwell Interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat. Brain Research Bulletin 1992;29:243–246.
78. S.Toulmond, N.J.Rochwell Interleukin-1 receptor antagonist inhibits neuronal damage caused by fluid percussion injury in the rat. Brain Research 1995;671:261–266.
79. A.Basu, J.K.Krady, M.O’Malley, S.D.Styren, S.T.Dekosky, S.W.Levison The type 1 interleukin-1 receptor is essential for the efficient activation of microglia and the induction of multiple pro-inflammatory mediators in response to brain injury. Journal of Neuroscience 2002;22:6071–6082.
80. R.Tehranian, S.Andell-Jonsson, S.M.Beni, I.Yatsiv, E.Shohami, T.Bartfai, J.Lundkvist, K.Iverfeldt Improved recovery and delayed cytokine induction after closed head injury in mice with central overexpression of the secreted isoform of the interleukin-1 receptor antagonist. Journal of Neurotrauma 2002;19:939–951.
81. C.M.Larsen, M.Faulenbach, A.Vaag, A.Valund, J.A.Ehses, B.Seifiri, T.Mandrup-Poulsen, M.Y.Donath Interleukin-1-receptor antagonist in type 2 diabetes mellitus. New England Journal of Medicine 2007;356:1517–1526.
82. B.W.Van Tasell, S.Toldo, E.Mezzaroma, A.Abbate Contemporary reviews in cardiovascular medicine:targeting interleukin-1 in heart disease. Circulation 2013;128:1910–1923.
83. J.A.Lust, M.Q.Lacy, S.R.Zeldenrust, A.Dispenzieri, M.A.Gertz, T.E.Witzig, S.Kumar, S.R.Hayman, S.J.Russell, F.K.Buadi, et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin-1 beta induced interleukin-6 production and the myeloma proliferative component. Mayo Clinic Proceedings 2009;84:114–122.
84. P.Q.Eichacker, C.Parent, A.Kalil, C.Esposito, X.Cui, S.M.Banks, E.P.Gerstenberger, Y.Fitz, R.L.Danner, C.Natanson Risk and the efficacy of anti-inflammatory agents:Retrospective and confirmatory studies of sepsis. American Journal of Respiratory & Critical Care Medicine 2002;166:1197–1205.
85. H.C.Emsley, C.J.Smith, R.F.Georgiou, A.Vail, S.J.Hopkins, N.J.Rothwell, P.J.Tyrrell; A.S.InvestigatorsAcute Stroke. A randomized phase II study of interleukin-1 receptor antagonist in acute stroke patients. Journal of Neurology, Neurosurgery & Psychiatry 2005;76:1366–1372.
86. A.Helmy, M.R.Guilfoyle, K.L.H.Carpenter, J.D.Pickard, D.K.Menon, P.J.Hutchinson Recombinant human interleukin-1 receptor antagonist in severe traumatic brain injury:a phase II randomized control trial. Journal of Cerebral Blood Flow & Metabolism 2014;34:845–851.
87. M.C.Genovese, S.Cohen, L.Moreland, D.Lium, S.Robbins, R.Newmark, P.Bekker Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis & Rheumatology 2014;50:1412–1419.
88. L.Helson, S.Green, E.Carswell, L.J.Old Effect of tumor necrosis factor on cultured human melanoma cells. Nature 1975;258:731–732.
89. S.Mirza, M.Hossain, C.Mathews, P.Martinez, P.Pino, J.L.Gay, A.Rentfro, J.B.McCormick, S.P.Fisher-Hoch Type-2 diabetes is associated with elevated levels of TNF-alpha, IL-6 and adiponectin and low levels of leptin in a population of Mexican Americans:a cross-sectional study. Cytokine 2012;57:136–142.
90. R.Ferrari The role of TNF in cardiovascular disease. Pharmacological Research 1999;40:97–105.
91. O.H.Nielsen, M.A.Ainsworth Tumor necrosis factor inhibitors for inflammatory bowel disease. New England Journal of Medicine 2013;360:754–762.
92. W.Swardfager, K.Lanctot, L.Rothenburg, A.Wong, J.Cappell, N.Herrmann A meta-analysis of cytokines in Alzheimer’s disease. Biological Psychiatry 2010;68:930–941.
93. V.Fontaine, S.Mohand-Said, N.Hanoteau, C.Fuchs, K.Pfizenmaier, U.Eisel Neurodegenerative and neuroprotective effects of tumor Necrosis factor (TNF) in retinal ischemia:opposite roles of TNF receptor 1 and TNF receptor 2. Journal of Neuroscience 2002;22:RC216.
94. E.Taoufik, V.Tseveleki, S.Y.Chu, T.Tselios, M.Karin, H.Lassmann, D.E.Szymkowski, L.Probert Transmembrane tumour necrosis factor is neuroprotective and regulates experimental autoimmune encephalomyelitis via neuronal nuclear factor-kappaB. Brain 2011;134:2722–2735.
95. S.M.Knoblach, L.Fan, A.I.Faden Early neuronal expression of tumor necrosis factor-alpha after experimental brain injury contributes to neurological impairment. Journal of Neuroimmunology 1999;95:115–125.
96. C.C.Chio, J.W.Lin, M.W.Chang, C.C.Wang, J.R.Kuo, C.Z.Yang, C.P.Chang Therapeutic evaluation of etanercept in a model of traumatic brain injury. Journal of Neurochemistry 2010;115:921–929.
97. C.C.Chio, C.H.Chang, C.C.Wang, C.U.Cheong, C.M.Chao, B.C.Cheng, C.Z.Yang, C.P.Chang Etanercept attenuates traumatic brain injury in rats by reducing early microglial expression of tumor necrosis factor-α. BMC Neuroscience 2013;14:33.
98. M.A.Ekici, O.Uysal, H.I.Cikriklar, Z.Ozbek, D.Turgut-Cosan, C.Baydemir, B.Kazanci, D.Hafizoglu Effect of etanercept and lithium chloride on preventing secondary tissue damage in rats with experimental diffuse severe brain injury. European Review for Medical & Pharmacological Science 2014;18:10–27.
99. C.U.Cheong, C.P.Chang, C.M.Chao, B.C.Cheng, C.Z.Yang, C.C.Chio Etanercept attenuates traumatic brain injury in rats by reducing brain TNF-α contents and by stimulating newly formed neurogenesis. Mediators of Inflammation 2013;620837.
100. L.Wang, F.X.Wei, J.S.Cen, S.N.Ping, Z.Q.Li, N.N.Chen, S.B.Cui, Y.Wan, S.Y.Liu Early administration of tumor necrosis factor-alpha antagonist promotes survival of transplanted neural stem cells and axon myelination after spinal cord injury in rats. Brain Research 2014;1575:87–100.
101. K.B.Chen, K.Uchida, H.Nakajima, T.Yayama, T.Hirai, S.Watanabe, A.R.Guerrero, S.Kobayashi, W.Y.Ma, S.Y.Liu et al. Tumor necrosis factor-α antagonist reduces apoptosis of neurons and oligodendroglia in rat spinal cord injury. Spine 2011;36:1350–1358.
102. E.Shohami, R.Bass, D.Wallach, A.Yamin, R.Gallily Inhibition of tumor necrosis factor alpha (TNF alpha) activity in rat brain is associated with cerebroprotection after closed head injury. Journal of Cerebral Blood Flow & Metabolism 1996;16:378–384.
103. E.R.Detrait, B.Danis, Y.Lamberty, P.Foerch Peripheral administration of an anti-TNF-alpha receptor fusion protein counteracts the amyloid induced elevation of hippocampal TNF-alpha levels and memory deficits in mice. Neurochemistry International 2014;72:10–13.
104. F.Marchand, C.Tsantoulas, D.Singh, J.Grist, A.K.Clark, E.J.Bradbury, S.B.McMahon Effects of etanercept and minoclycline in a rat model of spinal cord injury. European Journal of Pain 2009;13:673–681.
105. A.Tuttolomondo, R.Pecoraro, A.Pinto Studies of selective TNF inhibitors in the treatment of brain injury from stroke and trauma:a review of the evidence. Drug Design, Development & Therapy 2014;8:2221–2239.
106. E.Tobinick, N.M.Kim, G.Reyzin, H.Rodriguez-Romanacce, V.DePuy Selective TNF inhibition for chronic stroke and traumatic brain injury:an observational study involving 629 consecutive patients treated with perispinal etanercept. CNS Drugs 2012;26:1051–1070.
107. M.C.Morganti-Kossmann, M.Rancan, P.F.Stahel, T.Kossman Inflammatory response in acute traumatic brain injury:a double-edged sword. Current Opinion in Critical Care 2012;8:101–105.
108. M.Erta, A.Quintana, J.Hidalgo Interleukin-6, a major cytokine in the central nervous system. International Journal of Biological Sciences 2012;8:1254–1266.
109. E.J.Ley, M.A.Clond, M.B.Singer, D.Shouhed, Salim A. Il6 deficiency affects function after traumatic brain injury. Journal of Surgcai Research 2011;170:253–256.
110. C.D.Winter, A.K.Pringle, G.F.Clough, M.K.Church Raised parenchymal interleukin-6 levels correlate with improved outcome after traumatic brain injury. Brain 2004;127:315–320.
111. S.M.Conroy, V.Nguyen, L.A.Quina, P.Blakely-Gonzales, C.Ur, J.G.Netzeband, A.L.Prieto, D.L.Gruol Interleukin-6 produces neuronal loss in developing cerebellar granule neuron cultures. Journal of Neuroimmunology 2004;155:43–54.
112. A.V.Kalueff, K.A.Lehtimaki, A.Ylinen, J.Honkaniemi, J.Peltola Intranasal administration of human IL-6 increases the severity of chemically induced seizures in rats. Neuroscienc Letters 2004;365:106–110.
113. H.Samland, S.Huitron-Resendiz, E.Masliah, J.Criado, S.J.Henriksen, I.L.Campbell Profound increase in sensitivity to glutamatergic-but not cholinergic agonist-induced seizures in transgenic mice with astrocyte production of IL-6. Journal of Neuroscience Research 2004;73:176–187.
114. S.H.Yang, M.Gangidine, T.A.Pritts, M.D.Goodman, A.B.Lentsch Interleukin 6 mediates neuroinflammation and motor coordination deficits after mild traumatic brain injury and brief hypoxia in mice. Shock 2013;40:471–475.
115. S.Okada, M.Nakamura, Y.Mikami, T.Shimazaki, M.Mihara, Y.Ohsugi, Y.Iwamoto, K.Yoshizaki, T.Kishimoto, Y.Toyama, et al. Blockade of interleukin-6 receptor suppresses reactive astrogliosis and ameliorates functional recovery in experimental spinal cord injury. Journal of Neuroscience Research 2004;76:265–276.
116. M.Nakamura, S.Okada, Y.Toyama, H.Okano Role of IL-6 in spinal cord injury in a mouse model. Clinical Review in Allergy & Immunology 2005;28:197–204.
117. P.J.Crack, M.Zhang, M.C.Morganti-Kossmann, A.J.Morris, J.M.Wojciak, J.K.Fleming, I.Karve, D.Wright, M.Sashindranath, Y.Goldshmit, et al. Anti-lysophosphatidic acid antibodies improve traumatic brain injury outcomes. Journal of Neuroinflammation 2014;11:37.
118. S.Suzuki, K.Tanaka, N.Suzuki Ambivalent aspects of interleukin-6 in cerebral ischemia:inflammatory versus neurotrophic aspects. Journal of Cerebral Blood Flow & Metabolism 2009;29:464–479.
119. A.Kaneko Tocilizumab in rheumatoid arthritis:efficacy, safety and its place in therapy. Therapeutic Advances in Chronic Disease 2013;4:15–21.
120. S.M.Opal, V.A.DePalo Anti-inflammatory cytokines. Chest 2000;117:1162–1172.
121. E.Csuka, M.C.Morganti-Kossmann, P.M.Lenzlinger, H.Joller, O.Trentz, T.Kossmann IL-10 levels in cerebrospinal fluid and serum of patients with severe traumatic brain injury:relationship to IL-6, TNF-alpha, TGF-beta1 and blood-brain barrier function. Journal of Neuroimmunology 1999;101:211–221.
122. R.G.Kumar, J.A.Boles, A.K.Wagner Chronic inflammation after severe traumatic brain injury:characterization and associations with outcome at 6 and 12 months post injury. Journal of Head Trauma Rehabilitation 2014;30:369–381.
123. A.Bachis, A.M.Colangelo, S.Vicini, P.P.Doe, M.A.De Bernardi, G.Brooker, I.Mocchetti Interleukin-10 prevents glutamate-mediated cerebellar granule cell death by blocking caspase-3-like activity. Journal of Neuroscience 2001;21:3104–3112.
124. S.M.Knoblach, A.I.Faden Interleukin-10 improves outcome and alters proinflammatory cytokine expression after experimental traumatic brain injury. Experimental Neurology 1998;153:143–151.
125. X.Chen, X.S.Duan, L.J.Xu, J.J.Zhao, Z.F.She, W.W.Chen, Z.J.Zheng, G.D.Jiang Interleukin-10 mediates the neuroprotection of hyperaric oxygen therapy against traumatic brain injury in mice. Neuroscience 2014;266:235–243.
126. J.R.Bethea, H.Nagashima, M.C.Acosta, C.Briceno, F.Gomez, A.E.Marcillo, K.Loor, J.Green, W.D.Dietrich Systemically administered interleukin-10 reduces tumor necrosis factor-alpha production and significantly improves functional recovery following traumatic spinal cord injury in rats. Journal of Neurotrauma 1999;16:851–863.
127. K.L.Brewer, J.R.Bethea, R.P.Yezierski Neuroprotective effects of interleukin-10 following excitotoxic spinal cord injury. Experimental Neurology 1999;159:484–493.
128. K.E.Abraham, D.McMillen, K.L.Brewer The effects of endogenous interleukin-10 on gray matter damage and the development of pain behaviors following excitotoxic spinal cord injury in the mouse. Neuroscience 2004;124:945–952.
129. G.J.Marlow, D.van Gent, L.R.Ferguson Why interleukin-10 supplementation does not work in Crohn’s disease patients. World Journal of Gastroenterology 2013;19:3931–3941.
130. F.J.Dumont Therapeutic potential of IL-10 and its viral homologues:an update. Expert Opinion on Therapeutic Patents 2003;13:1551–1577.
131. W.B.Smith, L.Noack, Y.Khew-Goodall, S.Isenmann, M.A.Vadas, J.R.Gamble Transforming growth factor-beta 1 inhibits the production of IL-8 and the transmigration of neutrophils through activated endothelium. Journal of Immunology 1996;157:360–368.
132. D.Lindholm, E.Castrén, R.Kiefer, F.Zafra, H.Thoenen Transforming growth factor-beta 1 in the rat brain:increase after injury and inhibition of astrocyte proliferation. Journal of Cellular Biology 1992;117:395–400.
133. A.Buisson, S.Lesne, F.Docagne, C.Ali, O.Nicole, E.T.MacKenzie, D.Vivien Transforming growth factor-beta and ischemic brain injury. Cellular & Molecular Neurobiology 2003;23:539–550.
134. R.L.Roof, S.W.Hoffman, D.G.Stein Progesterone protects against lipid peroxidation following traumatic brain injury in rats. Molecular & Chemical Neuropathology 1997;31:1–11.
135. I.Sayeed, D.G.Stein Progesterone as a neuroprotective factor in traumatic and ischemic brain injury. Progress in Brain Research 2009;175:219–237.
136. C.A.O’Connor, I.Cernak, F.Johnson, R.Vink Effects of progesterone on neurologic and morphologic outcome following diffuse traumatic brain injury in rats. Experimental Neurology 2007;205:145–153.
137. C.L.Robertson, A.Puskar, G.E.Hoffman, A.Z.Murphy, M.Saraswati, G.Fiskum Physiologic progesterone reduces mitochondrial dysfunction and hippocampal cell loss after traumatic brain injury in female rats. Experimental Neurology 2006;197:235–243.
138. A.F.De Nicola, F.Labombarda, M.C.Gonzalez Deniselle, S.L.Gonzalez, L.Garay, M.Meyer, G.Gargiulo, R.Guennoun, M.Schmacher Progesterone neuroprotection in traumatic CNS injury and motoneuron degeneration. Frontier in Neuroendocrinology 2009;30:173–187.
139. S.M.Cutler, M.Cekic, D.M.Miller, B.Wali, J.W.VanLandingham, D.G.Stein Progesterone improves acute recovery after traumatic brain injury in the aged rat. Journal of Neurotrauma 2007;24:1475–1486.
140. J.He, C.O.Evans, S.W.Hoffman, N.M.Oyesiku, D.G.Stein Progesterone and allopregnanolone reduce inflammatory cytokines after traumatic brain injury. Experimental Neurology 2004;189:404–412.
141. G.Chen, J.Shi, W.Jin, L.Wang, W.Xie, J.Sun, C.Hang Progesterone administration modulates TLRs/NF-kappaB signaling pathway in rat brain after cortical contusion. Annals of Clinical & Laboratory Science 2008;38:65–74.
142. D.S.Pan, W.G.Liu, X.F.Yang, F.Cao Inhibitory effect of progesterone on inflammatory factors after experimental traumatic brain injury. Biomedical & Environmental Sciences 2007;20:432–438.
143. G.Xiao, J.Wei, W.Yan, W.Wang, Z.Lu Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury:a randomized controlled trial. Critical Care 2008;12:R61.
144. C.L.Robertson, E.Fidan, R.M.Stanley, C.Noje, H.Bayir Progesterone for neuroprotection in pediatric traumatic brain injury. Pediatric Critical Care Medicine 2015;16:236–244.
145. B.E.Skolnick, A.I.Maas, R.K.Narayan, R.G.van der Hoop, T.MacAllister, J.D.Ward, N.R.Nelson, N.Stocchetti A clinical trial of progesterone for severe traumatic brain injury. New England Journal of Medicine 2014;371:2467–2476.
146. A.Chase Traumatic brain injury. No benefit of progesterone therapy in patients with TBI. Nature Reviews 2015;11:65.
147. S.F.Chen, T.H.Hung, C.C.Chen, K.H.Lin, Y.N.Huang, H.C.Tsai, J.Y.Wang Lovastatin improves histological and functional outcomes and reduces inflammation after experimental traumatic brain injury. Life Sciences 2007;81:288–298.
148. B.Li, A.Mahmood, D.Lu, H.Wu, Y.Xiong, C.Qu, M.Chopp Simvastatin attenuates microglia, astrocyte activation and decreases IL-1β level following traumatic brain injury. Neurosurgery 2009;65:179–186.
149. H.Wang, J.R.Lynch, P.Song, H.J.Yang, R.B.Yates, B.Mace, D.S.Warner, J.R.Guyton, D.T.Laskowitz Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury. Experimental Neurology 2007;206:59–69.
150. W.T.Lai, K.T.Lee, C.S.Chu, W.C.Voon, H.W.Yen, L.Y.Tsai, S.H.Sheu Influence of withdrawal of statin treatment on proinflammatory response and fibrinolytic activity in humans:an effect independent on cholesterol elevation. International Journal of Cardiology 2005;98:459–464.
151. K.T.Lee, W.T.Lai, C.S.Chu, L.Y.Tsai, H.W.Yen, W.C.Voon, S.H.Sheu Effect of withdrawal of statin on C-reactive protein. Cardiology 2004;102:166–170.
152. J.J.Li, Y.S.Li, J.M.Chu, C.Y.Zhang, Y.Wang, Y.Huang, J.Chen, J.Q.Yuan, Y.L.Huang Changes of plasma inflammatory markers after withdrawal of statin therapy in patients with hyperlipidemia. Clinica Chimica Acta 2006;366:269–273.
153. A.Orlando, D.Bar-Or, K.Salottolo, A.S.Levy, C.W.Mains, D.S.Slone, P.J.Offner Unintentional discontinuation of statins may increase mortality after traumatic brain injury in elderly patients:a preliminary observation. Journal of Clinical Medicine Research 2013;5:168–173.
154. E.B.Schneider, D.T.Efron, E.J.MacKenzie, F.P.Rivara, A.B.Nathens, G.J.Jurkovich Premorbid statin use is associated with improved survival and functional outcomes in older head-injured individuals. Journal of Trauma 2011;71:815–819.
155. J.Tapia-Perez, M.Sachez-Aquilar, J.G.Torres-Corzo, A.Gordillo-Moscoso, P.Martinez-Perez, P.Madeville, E.de la Cruz-Mendoza, J.Chalita-Williams Effect of rosuvastatin on amnesia and disorientation after traumatic brain injury (NCT003229758). Journal of Neurotrauma 2008;25:1011–1017.
156. M.Sanchez-Aquilar, J.H.Tapia-Perez, J.J.Sanchez-Rodriguez, J.M.Vinas-Rios, P.Martinez-Perez, E.de la Cruz-Mendoza, M.Sanchez-Reyna, J.G.Torres-Corzo, A.Gordillo-Moscoso Effect of rosuvastatin on cytokines after traumatic brain injury. Journal of Neurosurgery 2013;118:669–675.
157. S.Rasras, F.Rahbariyan, M.Khezri The effect of simvastatin on patients with traumatic brain injury. Journal of Injury & Violence Research 2012; 63:4(3 Suppl 1).
158. N.Bye, M.D.Habgood, J.K.Callaway, N.Malakooti, A.Potter, T.Kossman, M.C.Morganti-Kossman Transient neuroprotection by minocycline following traumatic brain injury is associated with attenuated microglial activation but no changes in cell apoptosis or neutrophil infiltration. Experimental Neurology 2007;204:220–233.
159. J.M.Ziebell, M.C.Morganti-Kossmann Involvement of pro- and anti-inflammatory cytokines and chemokines in the pathophysiology of traumatic brain injury. Neurotherapeutics 2010;7:22–30.
160. R.O.Sanchez Mejia, V.O.Ona, M.Li, R.M.Friedlander Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery 2001;48:1393–1399.
161. S.M.Lee, T.Y.Yune, S.J.Kim, D.W.Park, Y.K.Lee, Y.C.Kim, Y.J.Oh, G.J.Markelonis, T.H.Oh Minocylcline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat. Journal of Neurotrauma 2013;20:1017–1027.
162. J.Yrjanheikki, R.Keinanen, M.Pellikka, T.Hokfelt, J.Koistinaho Tetracyclines inhibit microglial activation and are neuroprotective in glial brain ischemia. Proceeding of the National Academy of Sciences 1998;95:15769–15774.
163. O.M.Uckun, F.Alagoz, M.Secer, O.Karakoyun, A.Ocakcioglu, A.E.Yildirim, F.Yimaz, M.Sahinoglu, D.Divanlioglu, A.Dalgic, et al. Neuroprotective effects of tetracyclines on blunt head trauma:an experimental study on rats. Journal of Neurosciences in Rural Practice 2015;6:27–32.
164. E.Kovesdi, A.Kamnaksh, D.Wingo, F.Ahmed, N.E.Grunberg, J.B.Long, C.E.Kasper, D.V.Agoston Acute minocycline treatment mitigates the symptoms of mild blast-induced traumatic brain injury. Frontiers in Neurology 2012;3:111.
165. D.P.Stirling, K.M.Koochesfahani, J.D.Steeves, W.Tetzlaff Minocycline as a neuroprotective agent. Neuroscientist 2005;11:308–322.
166. L.Turtzo, N.Janaria, J.Lescher, J.Tu, J.Frank Efficacy of minocycline in female rats after mild diffuse traumatic brain injury (15-1B). Neurology 2015; 84:(Suppl P7.175).
167. M.Tsuji, M.A.Wilson, M.S.Lange, M.V.Johnston Minocycline worsens hypoxic-ischemic brain injury in a neonatal mouse model. Experimental Neurology 2004;189:58–65.
168. E.Diguet, C.E.Gross, F.Tison, E.Bezard Rise and fall of minocycline in neuroprotection:Need to promote publication of negative results. Experimental Neurology 2004;189:1–4.
169. K.Ding, H.Wang, J.Xu, X.Lu, L.Zhang, L.Zhu Melatonin reduced microglial activation and alleviated neuroinflammation induced neuron degeneration in experimental traumatic brain injury:possible involvement on mTOR pathway. Neurochemistry International 2014;76:23–31.
170. C.Mesenge, I.Margaill, C.Verrecchia, M.Allix, R.G.Boulu, M.Plotkine Protective effect of melatonin in a model of traumatic brain injury in mice. Journal of Pineal Research 1998;25:41–46.
171. N.Senol, M.Naziroglu Melatonin reduces traumatic brain injury-induced oxidative stress in the cerebral cortex and blood of rats. Neural Regeneration Research 2014;9:1112–1116.
172. D.Ozdemir, N.Uysal, S.Gonenc, O.Acikgoz, A.Sonmez, A.Topcu, N.Ozdemir, M.Duman, I.Semin, H.Ozkan Effect of melatonin on brain oxidative damage induced by traumatic brain injury in immature rats. Physiological Research 2005;54:631–637.
173. M.Naseem, S.Parvez Role of melatonin in traumatic brain injury and spinal cord injury. Scientific World Journal 2014;586270:13.
174. H.T.Zhu, C.Bian, J.C.Yuan, W.H.Chu, X.Xiang, F.Chen, C.S.Wang, H.Feng, J.K.Lin Curcumin attenuates acute inflammatory injury by inhibiting the TLR4/MyD88/NF-κB signaling pathway in experimental traumatic brain injury. Journal of Neuroinflammation 2014;11:59.
175. S.Sharma, Z.Ying, F.Gomez-Pinilla A pyrazole curcumin derivative restores membrane homeostasis disrupted after brain trauma. Experimental Neurology 2010;226:191–199.
176. A.Wu, Z.Ying, D.Schubert, F.Gomez-Pinilla Brain and spinal cord interaction:a dietary curcumin derivative counteracts locomotor and cognitive deficits after brain trauma. Neurorehabilitation & Neural Repair 2011;25:322–342.
177. M.D.Laird, S.Sukumari-Ramesh, A.E.Swift, S.E.Meiler, J.R.Vender, K.M.Dhandapani Curcumin attenuates cerebral edema following traumatic brain injury in mice:a possible role for aquaporin-4? Journal of Neurochemistry 2010;113:637–648.
178. F.Samini, S.Samarghandian, A.Borji, G.Mohammadi, M.Bakanian Curcumin pretreatment attenuates brain lesion size and improves neurological function following traumatic brain injury in rat. Pharmacology Biochemistry & Behavior 2013;110:238–244.
179. M.L.Cho, W.U.Kim, S.Y.Min, D.J.Min, J.K.Min, S.H.Lee, S.H.Park, C.S.Cho, H.Y.Kim Cyclosporine differentially regulates interleukin-10, interleukin-15, and tumor necrosis factor α production by rheumatoid synoviocytes. Arthritis & Rheumatology 2002;46:42–51.
180. T.T.Myrillas, G.J.Linden, J.J.Marley, C.R.Irwin Cyclosporin A regulates interleukin-1beta and interleukin-6 expression in gingiva:implications for gingival overgrowth. Journal of Periodontology 1999;70:294–300.
181. J.F.Gauchat, E.W.Khandjian, W.R.CyclosporinWeil R. A prevents induction of the interleukin 2 receptor gene in cultured murine thymocytes. Proceedings of the National Academy of Sciences 1986;83:6430–6434.
182. D.E.Tracey, M.M.Hardee, K.A.Richard, J.W.Paslay Pharmacological inhibition of interleukin-1 activity on T cells by hydrocortisone, cyclosporine, prostaglandins, and cyclic nucleotides. Immunopharmacology 1988;15:47–62.
183. T.J.Kilbaugh, S.Bhandare, D.H.Lorom, M.Saraswati, C.L.Robertson, S.S.Margulies Cyclosporin A preserves mitochondrial function after traumatic brain injury in the immature rat and piglet. Journal of Neurotrauma 2011;28:763–774.
184. J.Hatton, B.Rosbolt, P.Empey, R.Kryscio, B.Young Dosing and safety of cyclosporine in patients with severe brain injury. Journal of Neurosurgery 2008;109:699–707.
185. N.Nighoghossian, Y.Berthezene, L.Mechtouff, L.Derex, T.H.Cho, T.Ritzenthaler, S.Rheims, E.Chauveau, Y.Bejot, A.Jacquin, et al. Cyclosporine in acute ischemic stroke. Neurology 2015:84:2216–2223.
186. O.Thau-Zuchman, E.Shohami, A.G.Alexandrovich, V.Trembovler, R.R.Leker The anti-inflammatory drug carprofen improves long-term outcome and induces gliogenesis after traumatic brain injury. Journal of Neurotrauma 2012;29:375–384.
187. H.F.Lee, T.S.Lee, Y.R.Kou Anti-inflammatory and neuroprotective effects of triptolide on traumatic brain injury in rats. Respiratory Physiology & Neurobiology 2012;182:1–8.
188. J.Y.Oh, G.W.Roddy, H.Choi, R.H.Lee, J.H.Ylostalo, R.R.H.JrRosa RH. D.J.Prockop Anti-inflammatory protein TSG-6 reduces inflammatory damage to the cornea following chemical and mechanical injury. Proceedings of the National Academy of Sciences 2010;107:16875–16880.
189. J.Watanabe, A.K.Shetty, B.Hattiangady, D.K.Kim, J.E.Foraker, H.Nishida, D.J.Prockop Administration of TSG-6 improves memory after traumatic brain injury in mice. Neurobiology of Disease 2013;59:86–99.
190. A.D.Bachstetter, S.J.Webster, D.S.Goulding, J.E.Morton, S.M.Watterson, L.J.Van Eldik Attenuation of traumatic brain injury-induced cognitive impairment in mice by targeting increased cytokine levels with a small molecule experimental therapeutic. Journal of Neuroinflammation 2015;12:69–77.
191. R.Zhang, Y.Liu, K.Yan, L.Chen, X.R.Chen, P.Li, F.F.Chen, X.D.Jiang Anti-inflammatory and immunomodulatory mechanisms of mesenchymal stem cell transplantation in experimental traumatic brain injury. Journal of Neuroinflammation 2015;10:106.
192. D.G.Hernandez-Ontiveros, N.Tajiri, S.Acosta, B.Giunta, J.Tan, C.V.Borlongan Microglia activation as a biomarker for traumatic brain injury. Frontiers in Neurology 2013;4:30.
193. I.R.Niesman, J.M.Schilling, L.A.Shapiro, S.E.Kellerhals, J.A.Bonds, A.M.Kleschevnikov, W.Cui, A.Voong, S.Krajewski, S.S.Ali, et al. Traumatic brain injury enhances neuroinflammation and lesion volume in caveolin deficient mice. Journal of Neuroinflammation 2014;11:39.